Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority Phase III trail.

Chen Nan,Xing Changying,Niu Jianying,Liu Bicheng,Fu Junzhou,Zhao Jiuyang,Ni Zhaohui,Wang Mei,Liu Wenhu,Zhao Jinghong,Zhong Ling,Wu Xiongfei,Li Wenge,Chen Yuqing,Shi Wei,Chen Jianghua,Yin Aiping,Fu Ping,Wang Rong,Jiang Gengru,Hou Fanfan,Ding Guohua,Chen Jing,Xu Gang,Kondo Yuichiro,Su Yuliang,Mei Changlin
DOI: https://doi.org/10.1002/cdt3.13
2022-01-01
Chronic Diseases and Translational Medicine
Abstract:Darbepoetin alfa intravenously once per week can effectively increase Hb levels and maintain the target Hb levels well, which makes it not inferior to epoetin alfa intravenously twice or three times per week. Darbepoetin alfa shows an efficacy and safety comparable to epoetin alfa for the treatment of renal anemia.
What problem does this paper attempt to address?